ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess efficacy of aliskiren for reducing circulating levels
of biomarkers of left ventricular (LV) remodeling associated with LV hypertrophy (LVH) in
hypertensive patients.